Compounds > diphenylamine
Page last updated: 2024-08-21

diphenylamine and Nerve Sheath Neoplasms

diphenylamine has been researched along with Nerve Sheath Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chernoff, J; Deyev, SM; Dubyk, C; Handorf, E; Lazar, AJ; Semenova, G; Stepanova, DS1
Berry, P; Chikobava, L; Fischer-Huchzermeyer, S; Harder, A; Mautner, VF; Senner, V; Stahn, V; Veal, GJ; Zangarini, M1
Barretina, J; Chitalia, R; Dodd, L; Dodd, RD; Eward, WC; Kirsch, DG; Ma, Y; Mito, JK; Sachdeva, M1
Chapuis, N; Hivelin, M; Hubas, A; Lantieri, L; Laurendeau, I; Nusbaum, P; Parfait, B; Pasmant, E; Poulain, L; Varin, J; Vidaud, M; Wolkenstein, P1
Chaney, KE; Kendall, JJ; Largaespada, DA; Patel, AV; Ratner, N; Rizvi, TA1

Other Studies

5 other study(ies) available for diphenylamine and Nerve Sheath Neoplasms

ArticleYear
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
    Oncogene, 2017, 09-21, Volume: 36, Issue:38

    Topics: Animals; Benzamides; Cell Line, Tumor; Diphenylamine; Female; Humans; Mice; Mice, SCID; Molecular Targeted Therapy; Neoplasm Metastasis; Nerve Sheath Neoplasms; p21-Activated Kinases; Protein Kinase Inhibitors; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays

2017
Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.
    BMC research notes, 2018, Jul-28, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Diphenylamine; Heterografts; Humans; Mice; Mice, Nude; Nerve Sheath Neoplasms; Neurilemmoma; Sarcoma

2018
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Gene Deletion; Genes, Neurofibromatosis 1; Humans; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microvessels; Mitogen-Activated Protein Kinase Kinases; Nerve Sheath Neoplasms; Neurofibromin 1; Sarcoma

2013
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Oncotarget, 2016, Jun-14, Volume: 7, Issue:24

    Topics: Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Nerve Sheath Neoplasms; Neurofibroma, Plexiform; Neurofibromatosis 1; Neurofibromin 1; Nuclear Proteins; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Schwann Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors

2016
CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.
    Oncotarget, 2016, Aug-16, Volume: 7, Issue:33

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; beta Catenin; Casein Kinase II; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Synergism; Female; Humans; Mice, Nude; Naphthyridines; Nerve Sheath Neoplasms; Phenazines; Proteolysis; RNA Interference; Xenograft Model Antitumor Assays

2016